Bioxytran acquires NDPD Pharma for $15.85M in stock; CFO adopts 10b5-1 plan

BIOXYTRAN, INC

Acquired 100% of NDPD Pharma for stock: 3.39M common shares at $0.109 and 28.47M preferred shares at $0.543.
NDPD holds patents for ProLectin-M (COVID-19, RSV, H1N1, etc.) and a license agreement valued at $8.19M.
CFO Ola Soderquist adopted 10b5-1 plan to sell up to 500,000 common shares through March 31, 2025.
Consideration includes 14.1M Bioxytran preferred shares returned to treasury with a $4.0M book value.
Goodwill of $5.38M recorded; intangible assets amortized over 18 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.